drugset / Trial / NCT00514501

Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome

NCT00514501 ↗

Phase 2 Completed 510 enrolled Molecular Insight Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label phase 2 study recruiting low, moderate, and high likelihood ACS patients from approximately 60 centers. Patients will be imaged with iodofiltic acid I 123 for the detection of myocardial ischemia. Readers independent of the clinical study centers will review results of imaging studies in a blinded fashion at an imaging core lab. The resulting independent reading of the images will be compared against the truth standard for ACS.

Timeline

Start
2007-05
Primary completion
2008-06
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Iodofiltic acid I 123 Diagnostic / imaging agent 185 mbq —